All these results suggested that the inhibition of MCAM may have an effect on endothelial cells and tumor cells in vivo and encouraged the researches to use the MCAM target in studies in vivo, not only in melanoma but also in osteosarcoma, pancreatic tumors, and prostate cancer bone metastases [15,21,23,39]. This evidence concerns the gene MCAM and Familial prostate cancer.